{
"item_title" : "Hepatitis B",
"item_author" : [" Luis Rodrigo "],
"item_description" : "Current pharmacologic therapies for chronic hepatitis B virus (HBV) infection allow viral suppression and normalization of the liver enzyme alanine aminotransferase (ALT) and prevent liver disease from progressing. The currently available antiviral therapies very rarely lead to a functional cure. Thus, the future of a cure for HBV lies in triple combination therapies with concerted action on replication inhibition, antigen reduction, and immune stimulation. This book reviews the mechanisms and pathogenesis of HBV, as well as discusses current and potential future treatments.",
"item_img_path" : "https://covers1.booksamillion.com/covers/bam/1/80/355/006/1803550066_b.jpg",
"price_data" : {
"retail_price" : "155.00", "online_price" : "155.00", "our_price" : "155.00", "club_price" : "155.00", "savings_pct" : "0", "savings_amt" : "0.00", "club_savings_pct" : "0", "club_savings_amt" : "0.00", "discount_pct" : "10", "store_price" : ""
}
}
Overview
Current pharmacologic therapies for chronic hepatitis B virus (HBV) infection allow viral suppression and normalization of the liver enzyme alanine aminotransferase (ALT) and prevent liver disease from progressing. The currently available antiviral therapies very rarely lead to a functional cure. Thus, the future of a cure for HBV lies in triple combination therapies with concerted action on replication inhibition, antigen reduction, and immune stimulation. This book reviews the mechanisms and pathogenesis of HBV, as well as discusses current and potential future treatments.
This item is Non-Returnable
Customers Also Bought
Details
- ISBN-13: 9781803550060
- ISBN-10: 1803550066
- Publisher: Intechopen
- Publish Date: June 2022
- Dimensions: 9.61 x 6.69 x 0.38 inches
- Shipping Weight: 0.9 pounds
- Page Count: 128
Related Categories
